The GSK share price has had a rotten few years and now it's heading south yet again. Investor Harvey Jones continues to hang ...
If approved, the co-administration of Arexvy and Shingrix could provide a more convenient vaccination regimen for patients ...
Sometimes, a delay is caused by a patent review, so the PTO will compensate a pharmaceutical company by extending the life of ...
GSK (GSK) reached the main goal in a Phase 3 trial for its RSV shot, Arexvy co--administered with Shingles vaccine Shingrix.
GSK touts co-administration data for RSV, shingles vaccines as narrowed CDC guidance threatens sales
In the study, co-administration of GSK's RSV vaccine Arexvy and shingles shot Shingrix elicited non-inferior immune responses ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback